EGRX: Eagle Pharmaceuticals, Inc. Stock

by  •  • Comments Off on EGRX: Eagle Pharmaceuticals, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 55.06
Enterprise Value ($M) 55.06
Book Value ($M) 0.00
Book Value / Share 0.00
Price / Book n/a
NCAV ($M) 0.00
NCAV / Share 0.00
Price / NCAV n/a

Profitability (mra)
Return on Invested Capital (ROIC) n/a
Return on Assets (ROA) 0.00
Return on Equity (ROE) 0.00

Liquidity (mrq)
Quick Ratio n/a
Current Ratio n/a

Balance Sheet (mrq) ($M)
Current Assets 0.00
Assets 0.00
Liabilities 0.00
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
03-18 13G/A Tarriff Scott 17.60 -2.48
02-14 13D Graves Michael 1.80
02-13 13G/A Janus Henderson Group Plc 6.00 -36.94
02-13 13G/A Vanguard Group Inc 4.91 -16.45
02-12 13G Brandes Investment Partners, Lp 5.74
02-07 13G Hirschman Orin 8.20
01-26 13G/A BlackRock Inc. 7.60 -2.48
01-22 13G/A State Street Corp 1.71 -76.62

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2023-08-09 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO
2023-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S
2023-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-26 16,274 18,820 86.47
2024-04-25 21,941 35,353 62.06
2024-04-24 15,957 29,231 54.59
2024-04-23 13,986 40,792 34.29
2024-04-22 37,203 100,460 37.03

(click for more detail)

Similar Companies
CRSP – CRISPR Therapeutics AG CRVS – Corvus Pharmaceuticals, Inc.
CVAC – CureVac N.V. ELTX – Elicio Therapeutics, Inc.
ELYM – Eliem Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io